Jacobs Levy Equity Management Inc. Purchases 19,859 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jacobs Levy Equity Management Inc. increased its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 19.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 119,558 shares of the biotechnology company’s stock after purchasing an additional 19,859 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.44% of Arcturus Therapeutics worth $2,029,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Wellington Management Group LLP raised its holdings in shares of Arcturus Therapeutics by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock valued at $1,647,000 after purchasing an additional 742 shares during the period. Ameriprise Financial Inc. grew its stake in Arcturus Therapeutics by 5.0% in the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 883 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 1,132 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Arcturus Therapeutics by 7.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock valued at $323,000 after buying an additional 1,279 shares during the last quarter. Finally, Brevan Howard Capital Management LP grew its stake in Arcturus Therapeutics by 13.7% in the 4th quarter. Brevan Howard Capital Management LP now owns 12,305 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 1,486 shares during the last quarter. 94.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ARCT shares. Citigroup restated a “buy” rating on shares of Arcturus Therapeutics in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, Wells Fargo & Company dropped their price objective on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $57.80.

Arcturus Therapeutics Stock Performance

ARCT stock opened at $11.64 on Friday. The company has a fifty day moving average price of $11.57 and a 200-day moving average price of $15.27. The company has a market capitalization of $315.69 million, a P/E ratio of -5.24 and a beta of 2.36. Arcturus Therapeutics Holdings Inc. has a 52-week low of $8.04 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $1.06. The firm had revenue of $29.38 million during the quarter, compared to the consensus estimate of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, sell-side analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.